High Flow Nasal Cannula Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 12.40 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
High Flow Nasal Cannula Market Analysis
The global high-flow nasal cannula market is projected to witness a CAGR of nearly 12.4% over the forecast period (2022 - 2027).
The COVID-19 pandemic has significantly impacted the high-flow nasal cannula market. Several studies were carried out indicating the use of high-flow nasal cannula for COVID-19 patients. For instance, according to an article published by Multidisciplinary Respiratory Medicine, in September 2020, titled " High-flow nasal cannula for Acute Respiratory Distress Syndrome (ARDS) due to COVID-19", a retrospective, observational study was performed at a single center, evaluating patients with ARDS secondary to COVID-19 treated with a high-flow nasal cannula. In addition, high-flow therapy is found to be an effective treatment for ARDS that can be used to delay intubation or as a bridge therapy. Also, no higher mortality was seen as a result of this delay. Similarly, as per an article published by JAMA Network Journal, in December 2021, titled "Effect of High-Flow Oxygen Therapy vs Conventional Therapy on Invasive Mechanical Ventilation and Clinical Recovery in Patients with Severe COVID-19", it has been observed that high-flow oxygen therapy reduced the need for invasive mechanical ventilation and ramped up clinical recovery in patients with severe COVID-19 as compared to conventional oxygen therapy. Thus, the increased usage and clinical recovery of patients with high-flow oxygen therapy with nasal cannula during the pandemic are expected to increase the demand for the high-flow nasal cannula, thereby boosting the market growth.
The major factors contributing to the market growth are the rising incidences of respiratory disorders and increasing technological advancements in the high-flow nasal cannula systems.
The rising incidences of respiratory disorders are the key factor driving the market growth. For instance, according to the 2022 statistics published by the Australian Bureau of Statistics, 10.7% of the total population has asthma in 2020-2021. In addition, as per the same source, the highest prevalence of asthma was found in females (12%) as compared to males (9.4%). Moreover, according to the same source, the rate of asthma in boys and girls aged 0-14 years was 9.5% and 7.9%, respectively. Also, according to a December 2021 published article titled, high-flow nasal cannula in children with asthma exacerbation: A review of current evidence, high-flow oxygen therapy administered through a nasal cannula (HFNC) provides respiratory support with adequate airway humidity and has demonstrated safety and benefits in clinical practice. Thus, the growing burden of asthma is contributing to the increasing demand for high-flow nasal cannulas. Thus, the rising burden of respiratory diseases among the population is expected to rise the demand for high-flow oxygen therapy through a nasal cannula, which is expected to rise the market growth over the forecast period.
However, the limitations associated with high-flow nasal cannula are a major factor restraining the market growth.
High Flow Nasal Cannula Market Trends
This section covers the major market trends shaping the High Flow Nasal Cannula Market according to our research experts:
Nasal Cannula Expected to Hold Major Market Share
By component, the nasal cannula is expected to hold a major share of the market over the forecast period owing to the factors such as the increasing number of product launches and the rising burden of respiratory disorders that increase the demand for such devices. The nasal cannula is used to supply oxygen to a person who cannot get enough oxygen to sustain normal body functioning. It is commonly used for people with lung diseases like chronic obstructive pulmonary disease or acute illness.
The increasing prevalence of respiratory diseases is the key factor driving the demand for the nasal cannula, thereby boosting the segment growth. For instance, The European Respiratory Journal article titled 'An estimate of the European prevalence of COPD in 2050' published in November 2021 reported that 36,580,965 Europeans are living with chronic obstructive pulmonary disorder (COPD) in 2020. In addition, this number is projected to reach 49,453,852 by 2050 accounting for a 35.2% relative increase in patients and a 39.6% increase in prevalence. Such a growing burden of disease is also propelling the growth of the market segment.
Furthermore, the increasing company activities and rising adoption of various business strategies such as product launches, collaboration, and partnerships are expected to increase the demand for the nasal cannula, which further propels the market growth. For instance, in March 2020, Masimo, a global leader in innovative noninvasive monitoring technologies, entered into a definitive agreement to acquire TNI medical AG, an innovative ventilation company headquartered in Würzburg, Germany. This acquisition will assist the company to expand its offerings by leveraging TNI's deep engineering and commercial expertise and delivering its technology to a large and growing global market for therapy with nasal insufflation.
Thus, due to the above-mentioned developments, the market is expected to witness significant growth during the forecast period.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America is expected to dominate the global market throughout the forecast period owing to the factors such as the presence of key players, the high prevalence of respiratory diseases in the region, and the established healthcare infrastructure.
The increasing incidences of respiratory disorders in the country are a major factor driving the market growth. For instance, according to the statistics published by the Asthma and Allergy Foundation of America (AAFA), in April 2022, about 25 million people in America had asthma, in 2020, which is roughly 1 in 13 Americans. As per the same source, about 5.1 million American children have asthma under the age of 18. In addition, the prevalence of asthma is high in females (9.8%) as compared to males (6.1%). Also, as per the Interactive Summary Health Statistics for Adults by the Centers for Disease Control (CDC), 3.5% of the adult population had asthma in 2020. Thus, patients with a respiratory illness often require high-flow oxygen therapy through nasal cannula thus increasing the demand for the nasal cannula, thereby boosting the market growth.
Moreover, the market players are adopting various strategies, such as collaborations, partnerships, and product launches, which are showing a positive impact on the high-flow nasal cannula market. For instance, in August 2020, 3B Medical launched the Freedom X oxygen cannula intended to address the nostril irritation caused to patients by nasal cannulas, in the United States. Thus, the increasing product launches are expected to fuel the market growth in the region.
Thus, due to the above-mentioned developments, the market is expected to show lucrative growth over the forecast period.
High Flow Nasal Cannula Industry Overview
The high-flow nasal cannula market is moderately competitive and consists of several major players. Some of the companies currently dominating the market are ResMed, Fisher & Paykel Healthcare Limited, Devatec, Teleflex Incorporated, Smiths Medica, Vapotherm, Hamilton Medical, Flexicare Medical Limited, Masimo, and Great Group Medical Co. Ltd.
High Flow Nasal Cannula Market Leaders
-
ResMed
-
Fisher & Paykel Healthcare Limited
-
Devatec
-
Teleflex Incorporated
-
Smiths Medical
*Disclaimer: Major Players sorted in no particular order
High Flow Nasal Cannula Market News
- In August 2021, ResMed launched AirSense 11 in the United States, the company's next-generation PAP (positive airway pressure) device designed for therapy to treat and manage obstructive sleep apnea.
- In February 2021, Masimo launched softFlow high-flow nasal cannula therapy in the United States. It provides nasal high-flow warmed and humidified respiratory gases to spontaneously breathing patients. The technology, available on the softFlow 50, offers adult patients high-flow respiratory support through a soft nasal cannula by generating a consistently high flow of warm, humidified air or air/oxygen mixture.
High Flow Nasal Cannula Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Incidence of Respiratory Disorders
- 4.2.2 Technological Advances in the High-flow Nasal Cannula Systems
-
4.3 Market Restraints
- 4.3.1 Limitations of the High-flow Nasal Cannula Therapy
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value -USD million)
-
5.1 By Component
- 5.1.1 Air/Oxygen Blender
- 5.1.2 Active Humidifier
- 5.1.3 Single Heated Tube
- 5.1.4 Nasal Cannula
- 5.1.5 Other Consumables
-
5.2 By Application
- 5.2.1 Acute Respiratory Failure
- 5.2.2 Chronic Obstructive Pulmonary Disease
- 5.2.3 Acute Heart Failure
- 5.2.4 Other Applications
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle-East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle-East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 ResMed
- 6.1.2 Fisher & Paykel Healthcare Limited
- 6.1.3 Devatec
- 6.1.4 Teleflex Incorporated
- 6.1.5 Smiths Medical
- 6.1.6 Vapotherm
- 6.1.7 Hamilton Medical
- 6.1.8 Flexicare Medical Limited
- 6.1.9 Masimo (TNI medical AG)
- 6.1.10 Great Group Medical Co. Ltd
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityHigh Flow Nasal Cannula Industry Segmentation
As per the scope of the report, high-flow nasal cannula (HFNC) oxygen therapy is carried out using an air/oxygen blender, active humidifier, single heated tube, and nasal cannula, which can deliver adequately heated and humidified medical gas at flows up to 60 L/min. The market is segmented by Component (Air/Oxygen Blender, Active Humidifier, Single Heated Tube, Nasal Cannula, and Other Consumables), Application (Acute Respiratory Failure, Chronic Obstructive Pulmonary Disease, Acute Heart Failure, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Component | Air/Oxygen Blender | |
| Active Humidifier | ||
| Single Heated Tube | ||
| Nasal Cannula | ||
| Other Consumables | ||
| By Application | Acute Respiratory Failure | |
| Chronic Obstructive Pulmonary Disease | ||
| Acute Heart Failure | ||
| Other Applications | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
High Flow Nasal Cannula Market Research FAQs
What is the current Global High-flow Nasal Cannula Market size?
The Global High-flow Nasal Cannula Market is projected to register a CAGR of 12.40% during the forecast period (2024-2029)
Who are the key players in Global High-flow Nasal Cannula Market?
ResMed, Fisher & Paykel Healthcare Limited, Devatec, Teleflex Incorporated and Smiths Medical are the major companies operating in the Global High-flow Nasal Cannula Market.
Which is the fastest growing region in Global High-flow Nasal Cannula Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global High-flow Nasal Cannula Market?
In 2024, the North America accounts for the largest market share in Global High-flow Nasal Cannula Market.
What years does this Global High-flow Nasal Cannula Market cover?
The report covers the Global High-flow Nasal Cannula Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global High-flow Nasal Cannula Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global High-flow Nasal Cannula Industry Report
Statistics for the 2024 Global High-flow Nasal Cannula market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global High-flow Nasal Cannula analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
